Indian government is working actively to stop black marketing of medicines in the future

New Delhi : National Pharmaceutical Pricing Authority (NPPA) has taken one step forward and fixed ceiling price (CP) of 1 scheduled formulation and Maximum Retail Price (MRP) of 4 formulations to stop black marketing.

NPPA revised prices under Drugs (Price Control) Amendment Order, 2016 (under DPCO, 2013) and retail prices of 4 formulations under DPCO, 2013. Clotrimazol’s ceiling price is fixed now and NPPA officials also added that the manufacturers of scheduled formulations, selling the branded / generic / both versions of scheduled formulations at a price higher than the ceiling price [plus local taxes as applicable] fixed and notified by the government, shall revise the prices.

Retail Price of four medicines Pacimol 10mg/ml Infusion, Pacimol MF tablet, Ten- DC M 500 tablet and Ten – DC M 1000 tablet MRP has been fixed under DPCO, 2013. Officials said we are now covering common medicines and started with major drugs and products like stents. The allowed price change is in the range of 10% to 15% only.  We are ensuring this step will definitely curb black marketing and benefits consumers.

To help consumers to aware them about the price change, retailers expected to show main and supplementary list if any, as furnished by the manufacturer. Deposits should be made with an interest in the case of overcharging under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

NPPA notified all manufacturers to maintain MRP in case if it is lower than capped price. Pharma manufacturers permitted to add local taxes if they have paid them or if it is payable to the government on the ceiling price mentioned.

LEAVE A REPLY

Please enter your comment!
Please enter your name here